What REDUCE-IT Actually Changes in Clinical Practice

At a glance

| Parameter | Detail | |---|---| | Trial name | REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) | | N | 8,179 | | Intervention | Icosapent ethyl 4 g/day (2 g twice daily) | | Comparator | Mineral oil placebo | | Duration | Median 4.9 years | | Primary endpoint | Composite of cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina | | Key result | HR 0.75 (95% CI 0.68-0.83; p < 0.001), absolute risk reduction 4.8% |

The Practice Gap Before REDUCE-IT

Before REDUCE-IT published in the New England Journal of Medicine in January 2019, the role of triglyceride-lowering therapy in cardiovascular prevention was uncertain. Two earlier omega-3 trials, VITAL and ASCEND, used low-dose mixed EPA/DHA formulations and showed no meaningful MACE benefit. Fibrates had similarly disappointed. Clinicians saw elevated triglycerides on lipid panels daily, but lacked a proven intervention beyond lifestyle counseling.

The clinical problem was real. Patients on maximally tolerated statins with triglycerides between 150 and 499 mg/dL carry measurable residual cardiovascular risk. Their LDL may be at goal, their statin adherence solid, and yet events keep happening. REDUCE-IT targeted exactly this population, enrolling patients with established cardiovascular disease (71%) or diabetes with at least one additional risk factor (29%) who had fasting triglycerides of 150-499 mg/dL despite statin therapy.

What the Trial Actually Showed

The primary analysis reported a 25% relative risk reduction in the five-point MACE composite. That headline number, while important, understates the consistency of the findings. Every component of the primary composite moved in the same direction:

| Endpoint | Icosapent ethyl (%) | Placebo (%) | HR (95% CI) | |---|---|---|---| | CV death | 4.3 | 5.2 | 0.80 (0.66-0.98) | | Nonfatal MI | 6.1 | 8.7 | 0.69 (0.58-0.81) | | Nonfatal stroke | 2.4 | 2.9 | 0.72 (0.55-0.93) (key secondary) | | Coronary revascularization | 7.2 | 9.1 | 0.65 (0.55-0.78) (key secondary) | | Unstable angina hospitalization | 2.4 | 3.2 | 0.68 (0.53-0.87) (key secondary) |

The key secondary composite (CV death, nonfatal MI, nonfatal stroke) showed a 26% reduction (HR 0.74; p < 0.001). The number needed to treat (NNT) over 4.9 years was 21 for the primary endpoint, which is competitive with the NNTs seen in landmark statin trials.

Critically, the benefit appeared early (separation of Kaplan-Meier curves visible by approximately 12-18 months) and grew over the full follow-up period. Subgroup analyses showed consistent benefit regardless of baseline triglyceride level, baseline EPA level, age, sex, diabetes status, or statin intensity.

The Mineral Oil Placebo Controversy

No discussion of REDUCE-IT's clinical translation is complete without addressing the mineral oil question. The placebo contained mineral oil, which raised LDL-C by approximately 10.9 mg/dL, raised hsCRP by 32%, and raised markers of oxidized LDL in the comparator arm. The FDA's Endocrinologic and Metabolic Drugs Advisory Committee scrutinized this at length during the December 2019 review.

The concern is straightforward: if mineral oil made the placebo group worse, the true effect size of icosapent ethyl is smaller than 25%. FDA panelists who voted in favor of approval (16-0 for the CV indication) concluded that even after adjusting for the mineral oil effect on biomarkers, the benefit signal remained statistically significant. Independent sensitivity analyses estimated that mineral oil may have inflated the HR by 3-5 percentage points, leaving a real treatment effect in the range of 20-22%.

The STRENGTH trial, which tested a carboxylic acid formulation of EPA+DHA against a corn oil placebo, found no MACE benefit. Some interpreted STRENGTH as evidence against all omega-3 therapy. Others pointed to critical design differences: STRENGTH used a combined EPA+DHA product, enrolled fewer high-risk patients, and was stopped early for futility. Whether the difference lies in the pure-EPA formulation, the placebo choice, or the population remains debated.

Which Guidelines Changed

REDUCE-IT forced concrete updates across multiple societies, each interpreting the data with slightly different emphasis.

AHA/ACC (2019 focused update on primary prevention, 2018 cholesterol guideline update): Added a IIa recommendation ("should be considered") for icosapent ethyl 4 g/day in patients with ASCVD or diabetes, triglycerides 135-499 mg/dL on maximally tolerated statins. This was the first time a triglyceride-lowering therapy received this grade. The 2019 ACC/AHA guideline on primary prevention explicitly distinguished icosapent ethyl from generic fish oil.

ESC/EAS (2019 dyslipidemia guidelines): The European Society of Cardiology gave icosapent ethyl a IIb recommendation for ASCVD patients with triglycerides between 135 and 499 mg/dL. The slightly weaker grade reflected European concern about the mineral oil placebo.

Endocrine Society and NLA: Both updated position statements to include icosapent ethyl as an option for residual cardiovascular risk after statin optimization, with the caveat that triglyceride levels alone should not drive the prescribing decision.

FDA labeling (December 2019): The agency approved an expanded indication for icosapent ethyl to reduce cardiovascular risk in statin-treated adults with triglycerides ≥ 150 mg/dL and established CVD or diabetes with ≥ 2 additional risk factors. This made Vascepa the first EPA-only product with a cardiovascular risk-reduction indication, distinct from the older triglyceride-lowering-only label.

How Prescribing Patterns Actually Shifted

Guideline updates do not automatically change prescribing. In the years following REDUCE-IT, several real-world patterns emerged.

Prescription volume increased but remained modest. Despite the strong trial result, icosapent ethyl prescriptions grew slowly. Cost was a significant barrier. Prior authorizations, high copays (before generic availability), and payer reluctance to cover what some formulary committees still categorized as "fish oil" slowed adoption. Many patients who met REDUCE-IT criteria never received the drug.

Clinician confusion with over-the-counter fish oil persisted. A recurring problem in practice: patients hearing "prescription EPA" and assuming their existing OTC omega-3 supplement was equivalent. OTC fish oil products are not bioequivalent to icosapent ethyl. They contain varying EPA/DHA ratios, are not manufactured under the same pharmaceutical controls, and have no MACE-reduction data. The VITAL trial's null result with low-dose EPA/DHA reinforces this distinction.

Cardiology adopted faster than primary care. Cardiologists, who managed the patients closest to the trial population, prescribed icosapent ethyl more readily. Primary care physicians, who manage the larger pool of diabetic patients with mild triglyceride elevation, were slower to integrate the drug into their workflow.

Who Benefits Most (and Who Might Not)

The REDUCE-IT population was specific: established CVD or high-risk diabetes, on statins, triglycerides 150-499 mg/dL. Applying these results to other populations requires caution.

Strongest case for use:

• Secondary prevention patients on statins with persistent triglyceride elevation (150-499 mg/dL)
• Diabetic patients with ≥ 2 additional CV risk factors and triglycerides in range
• Patients who have already had a MACE event despite statin therapy

Weaker case (extrapolation beyond trial data):

• Primary prevention patients without diabetes who have mild triglyceride elevation. REDUCE-IT enrolled only 29% primary-prevention patients, all of whom had diabetes
• Patients with very high triglycerides (≥ 500 mg/dL). These patients were excluded; they face different risks (pancreatitis) and may need different management
• Patients not on statin therapy. The trial required stable statin use; the benefit may depend on the combination

Uncertain territory:

• Whether the benefit is driven purely by EPA levels or partly by anti-inflammatory mechanisms. Prespecified analyses showed benefit across all baseline triglyceride quartiles, suggesting the mechanism may extend beyond triglyceride lowering. On-treatment EPA levels correlated with outcomes, but correlation is not mechanism
• Whether generic icosapent ethyl (available from 2020 after patent disputes) provides identical benefit. The FDA considers AB-rated generics therapeutically equivalent, but no outcomes trial has been conducted with a generic formulation

Safety Signals Worth Knowing

The trial identified a statistically significant increase in atrial fibrillation (5.3% vs. 3.9%) and atrial flutter in the icosapent ethyl group. Serious bleeding events were also numerically higher (2.7% vs. 2.1%), though the difference in adjudicated serious bleeding did not reach statistical significance. For patients with a history of atrial fibrillation or those on anticoagulation, the risk-benefit calculus requires individual assessment.

Peripheral edema and constipation were more common with icosapent ethyl. These side effects were generally mild but contributed to discontinuation in some patients.

What This Means for the Statin-Treated Patient Today

REDUCE-IT established a concrete answer to a question that lipidologists had debated for decades: yes, targeting triglyceride-associated residual risk with the right agent reduces hard cardiovascular events. The drug works. The NNT is reasonable. The effect is consistent across subgroups.

The practical translation is more nuanced. Not every patient with triglycerides above 150 mg/dL needs icosapent ethyl. The drug is appropriate when residual CV risk is meaningful despite statin therapy, when the triglyceride level falls within the studied range, and when the patient's bleeding risk and arrhythmia history have been weighed.

For clinicians, the key shift is conceptual. Before REDUCE-IT, elevated triglycerides on a statin-treated patient's lab panel were noted but rarely acted upon with pharmacotherapy. After REDUCE-IT, that triglyceride value becomes actionable, a prompt to assess whether the patient meets criteria for an intervention with proven MACE reduction.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. PubMed
2. Vascepa (icosapent ethyl) prescribing information. Amarin Pharma, Inc. Revised December 2019. FDA Label
3. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268-2280. PubMed
4. Manson JE, Cook NR, Lee IM, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer (VITAL). N Engl J Med. 2019;380(1):23-32. PubMed
5. Arnett DK, Blumenthal RS, Khera A, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019;140(11):e596-e646. PubMed
6. ASCEND Study Collaborative Group. Effects of n-3 fatty acid supplements in diabetes mellitus (ASCEND). N Engl J Med. 2018;379(16):1540-1550. PubMed